# Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

> **NCT07682961** · PHASE3 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 590 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lenacapavir
- **DRUG:** Lenacapavir Tablet
- **DRUG:** Teropavimab
- **DRUG:** Zinlirvimab
- **DRUG:** Cabotegravir
- **DRUG:** Rilpivirine

## Key facts

- **NCT ID:** NCT07682961
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-14
- **Primary completion:** 2029-03
- **Final completion:** 2033-03
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2026-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682961, "Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07682961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*